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Introduction: Studies on the transactivation of genes via pro-
moter elements have mostly been done on cell lines rather than
resected tissues. This, however, is essential to address an
in vivo or clinical relevance. We have previously shown tumor-
specific binding of Sp1and an activator protein (AP)-2a related fac-
tor to promoter region -152/-135 of the metastasis-related u-PAR
gene in 60% of in vivo resected cancer tissues. Cell lines have
implicated an additional role, and potential synergism, of an
AP-1 region (-190/-171) in u-PAR regulation. This study was done
to (a) analyze AP-1 binding to this region in resected tumor and
normal tissues, and define subgroups in which it is tumor-spe-
cific, and (b) to analyze transcription factor binding patterns to
both promoter motifs in resected tissues, supporting synergism,
and draw first prognostic conclusions.
Methods: In 103 patients with colorectal cancer, electrophoretic
mobility shift assay/supershift analysis for u-PAR promoter
region -190/-171 was done in tumors and normal tissues. In 71
patients, region -152/-135 was also analyzed. U-PAR protein was
measured by ELISA.
Results: Tumor-specific AP-1 binding to region -190/-171 of the u-
PAR promoter was found in 40% of patients. Subgroup analysis
showed tumor-specific binding for c-Fos in 58%, for c-Jun in
50%, for JunD in 39%, and for Fra-1 in 4% of cases. AP-1 binding
correlated significantly with u-PAR protein amounts in both nor-
mal and tumor tissues (p < 0.001), in contrast to a tumor-specific
correlation with u-PAR of the AP-2/Sp1 region. In analyses for
both promoter regions, 62% of cancers showed simultaneous
binding for AP-1, AP-2, and Sp1, 11% for AP-1 and AP-2, 16% for
AP-2 and Sp1, 4% for AP-2 only, 3% for AP-1 only, and 0% for
Sp1 only. The binding of AP-1, AP-2, and Sp1 correlated signifi-
cantly with each other (p < 0.001), the combination of AP-1 and
AP-2 showing the highest correlation with u-PAR (p = 0.008). Preli-
minary survival analysis indicated a trend for poorer prognosis
for binding of all three transcription factors.
Conclusion: This is the first study differentiating transcription
factor binding to two important u-PAR promoter regions in a large
series of resected tumors and normal tissues. The AP-1 site seems
to be a less tumor-specific regulator than the Sp1/AP-2 motif.
Nevertheless, data corroborate the hypothesis of synergism
between both elements in resected tumors.
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Background: Tumor-suppressor Pdcd4 has never been investi-
gated as to a potential role in invasion/metastasis. The urokinase
receptor (u-PAR) promotes invasion and metastasis and is associ-
ated with a poor cancer-patient survival. The present study was
conducted: (1) to implicate a role of Pdcd4 in invasion and u-
PAR-regulation, (2) to describe first mechanisms by which this is
achieved.
Methods: Diverse gastrointestinal carcinoma cell lines were
screened for Pdcd4- and u-PAR expression and protein amounts
by Northern-, Western blot analysis respectively RT-PCR. To deter-
mine a potential regulation of the u-PAR promoter by Pdcd4, CAT-
and luciferase reporter assays using diverse u-PAR wildtype and
deletions mutants were undertaken and potential cis-element
were screened for transcription factor binding by EMSA. Invasion
and intravasation influenced by Pdcd4 were tested by using differ-
ent invasion assay approaches.
Results: In colon/gastric cancer cell lines, a reciprocal expression
of u-PAR and Pdcd4 was observed. RKO and HCT116 colon cancer
cells made to express Pdcd4 showed a reduction in u-PAR-mRNA
and -protein, this being paralleled by an inhibition of invasion/
intravasation. A CAT-reporter driven by the wildtype u-PAR-pro-
moter was reduced in constitutive activity with increasing
Pdcd4-expression. Deletion of a region containing a putative
Sp-1 binding site at -402/-350 inhibited u-PAR-promoter regula-
tion by Pdcd4, this being paralleled by a reduction of Sp1 binding
to this region in pdcd4-transfected cells. Pdcd4-transfected
cells showed an increase of Sp3 binding to u-PAR-promoter region
-152/-135, and the deletion of this region reduced the ability of
Pdcd4 to suppress u-PAR-promoter activity.
Conclusion: These data suggest Pdcd4 as a new negative regula-
tor of invasion and the invasion-related gene u-PAR. Furthermore,
it is the first study to implicate Pdcd4-induced gene expression
via Sp3 induction and Sp1 suppression.
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